NCT06805305 - DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2032

Conditions

Glioblastoma (GBM)

Interventions

BIOLOGICAL

DOC1021

Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method

PROCEDURE

Tumor resection

SOC brain tumor resection

DRUG

Temodar (Temozolomide)

SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation

RADIATION

SOC cranial radiation

60Gy radiation over 6 weeks in 2Gy fractions

Trial Locations (9)

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

32207

RECRUITING

Baptist MD Anderson Cancer Center, Jacksonville

77030

RECRUITING

UTHealth Houston, Houston

78229

RECRUITING

The University of Texas Health Science Center at San Antonio, San Antonio

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

91010

RECRUITING

City of Hope, Duarte

08901

RECRUITING

Rutgers Cancer Institute, New Brunswick

07901

RECRUITING

Atlantic Health, Summit